Clinical Trials Logo

Filter by:
NCT ID: NCT01224366 Completed - Clinical trials for Type 2 Diabetes Mellitus

Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus

Start date: September 2010
Phase: Phase 3
Study type: Interventional

To assess the efficacy and safety of vildagliptin add-on therapy to reduce HbA1c in patients with T2DM inadequately controlled by insulin, with or without concurrent metformin therapy.

NCT ID: NCT01224197 Completed - Hepatitis C Clinical Trials

TMC435 HPC1004 - Phase I Study Investigating the Pharmacokinetics of TMC435 in Healthy Chinese Volunteers

Start date: October 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the pharmacokinetics, safety and tolerability of single and multiple oral doses of TMC435 in Chinese healthy volunteers. Pharmacokinetics (PK) means how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body.

NCT ID: NCT01221077 Completed - Clinical trials for Non Small Cell Lung Cancer

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Start date: April 8, 2011
Phase: Phase 2
Study type: Interventional

A multicenter, randomized, double-blind, placebo-controlled, phase 2 study of Erlotinib (Tarceva®) in combination with OSI-906 in Patients with Advanced non-small cell lung cancer (NSCLC) with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene who are Chemonaive.

NCT ID: NCT01217944 Completed - Pathological Myopia Clinical Trials

Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Start date: October 2010
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (PM).

NCT ID: NCT01215084 Completed - Healthy Clinical Trials

A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers

Start date: October 2010
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to determine the Pharmacokinetic (PK) and safety profiles of fampridine-PR 10 mg in Chinese and Japanese adult healthy volunteers. The secondary objective of this study is to compare the PK and safety profiles of fampridine-PR 10 mg among the Chinese, Japanese, and Caucasian adult healthy volunteers.

NCT ID: NCT01210495 Completed - Clinical trials for Hepatocellular Carcinoma

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

Start date: December 6, 2010
Phase: Phase 2
Study type: Interventional

The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.

NCT ID: NCT01208831 Completed - Clinical trials for Basal Cell Carcinoma

An East Asian Study of LDE225

Start date: October 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine Maximum Tolerated Dose (MTD) or recommended phase II dose of LDE225 when administered orally to two adult patient groups of East Asian (i.e., Japanese and Chinese/Taiwanese) with advanced solid tumors that have progressed despite standard therapy or for which no standard therapy exists.

NCT ID: NCT01207570 Completed - Cerebral Palsy Clinical Trials

Endermotherapy for Children With Developmental Disabilities

Start date: February 2010
Phase: Phase 2
Study type: Interventional

Children with developmental disabilities often sustain decreased range of motion in their extremities. The decrease in flexibility may be due to neuromuscular disorders such as spasticity or dystonia. Other causes may be imbalance in muscle strength surrounding a joint, leading to inappropriate habitual posture. Over time, muscle contracture may result for those muscle groups that are placed in a shortened position for an extended period of time. The most common site of muscle contractures among these children are gastrocnemius/soleus (lower limbs), and latissimus dorsi muscles (upper limbs). Muscle contractures can lead to further decline in functional abilities. Therefore, it is important to identify effective intervention strategies to enhance or maintain muscle flexibility in children with developmental dysfunctions. Commercially available endermotherapy device has been used to soften scar tissue following burn injuries. The mechanical stimulation applied may also have beneficial effects on relaxing the muscle tissue. The overall aim of the proposed study is to determine whether endermotherapy treatment has immediate effect in improving joint range of motion among children with developmental disabilities. The research hypothesis is that children in the endermotherapy group will have significantly more gain in ankle passive range of motion than those in the control group.

NCT ID: NCT01207544 Completed - Clinical trials for Developmental Coordination Disorder

Fitball Program Versus Task-oriented Motor Program on Improving Postural Control in Developmental Coordination Disorder

Start date: April 2010
Phase: N/A
Study type: Interventional

Children with developmental coordination disorder (DCD) often have poor postural control and motor skills that affect their activities of daily living and participation in school activities. The aim of this randomized controlled trial is to compare the effects of fitball training versus task-oriented motor training for children with DCD.

NCT ID: NCT01207219 Completed - Psychotic Disorder Clinical Trials

Yoga and Aerobic Exercise in Psychosis

YEP
Start date: November 2010
Phase: N/A
Study type: Interventional

The current study aims to evaluate the impacts of yoga and aerobic exercise on neuro-cognitive function, symptoms and brain changes in early psychosis. A total of 120 female subjects who aging from 18-55 years old, and diagnosed with psychotic disorders within the past 5 years, will be randomized into 3 groups: 1) yoga therapy, 2) aerobic exercise, and 3) waitlist group as the control. All groups will try to be kept consistent with their medication with no more than 25% change in their entry level dosage for at least six weeks. The primary outcomes of the present study will be neuro-cognitive changes; the secondary outcomes will be changes of brain structure and function.